Capivasertib–fulvestrant therapy resulted in significantly longer PFS than treatment with fulvestrant alone among patients with HR-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor. This evidence concerns the gene CYP19A1 and breast cancer.